Jonathan Wall, PhD, University of Tennessee Graduate School of Medicine, Knoxville, TN, comments on the challenges associated with current diagnostic methods in ATTR amyloidosis and highlights the benefits of PET/CT imaging in the diagnosis and monitoring of this disease. 124I AT-01, an amyloid-reactive synthetic peptide radiotracer, can be used to identify the location and amount of amyloid across the entire body both at diagnosis and across the patient’s journey. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Co-founder and shareholder in Attralus Inc. Inventor and patent holder related to amyloid-binding peptide technologies and amyloid-reactive antibody. Receive research funding from Attralus Inc.